Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SIBN vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 5–4 Matrix Metrics)
DCTH Overall Winner
6-Pillar Tally: SIBN 0 – 6 DCTH
Matrix Metrics: SIBN 4 – 5 DCTH
As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over SI-BONE, Inc. (SIBN) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SIBN carries a Unified Composite Score of 38.3/100 (SELL) at $23.29 (N/M Forward P/E, -7.6% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).
- Composite vs. Pillar Nuance: While SIBN currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -7.6% operating margin) and revenue trajectory (+70.7% vs. +14.5% YoY).
- Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both SIBN (38.3/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SIBN vs DCTH
SIBN
SI-BONE, Inc. Common Stock
$23.29
-0.64% 1D
Market Cap
$1.1B
TTM Revenue
$221M
Forward P/E
N/M
Beta / 30D Vol
0.74β · 77% Vol
Unified Composite Score
38.3
SELL
Tech 8.0
Fund 30.0
Flow 71.0
Mom 31.4
Weinstein Technical Phase
Markup · Hold / add on dips
DCTH
Head-to-Head Winner
Delcath Systems Inc
$19.68
-4.23% 1D
Market Cap
$743.8M
TTM Revenue
$110M
Forward P/E
N/M
Beta / 30D Vol
1.63β · 131% Vol
Unified Composite Score
35.9
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (SIBN 0 – 6 DCTH)
1. Valuation Multiples
DCTH
Forward P/E
N/M
N/M
Trailing P/E
N/M
133.6x
PEG Ratio
N/M
1.60x
EV / Revenue
5.0x
6.3x
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+14.5%
+70.7%
Earnings Growth (YoY)
+0.0%
+750.0%
TTM Revenue (USD)
$221M
$110M
Market Cap
$1.1B
$743.8M
3. Profitability & Quality
DCTH
Gross Margin
79.4%
87.6%
Operating Margin
-7.6%
5.2%
Net Profit Margin
-6.2%
6.0%
Return on Equity (ROE)
-7.7%
5.4%
4. Balance Sheet & Cash Flow
DCTH
Cash Generation (TTM)
-$4.2M
$20M
Cash Flow Margin
-1.9%
18.3%
Net Cash / Leverage
$7.5M Net Debt (0.23x D/E)
$53M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DCTH
Options Structure Phase
BREAKOUT
BREAKOUT
Current IV / %ile
44.5% (14th %ile)
109.3% (43rd %ile)
Put/Call OI Skew
N/A
0.11x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markup
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
N/A
82.4% of Rev ($91M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SIBN (4) vs DCTH (5)| Institutional Metric | SIBN | DCTH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.1B | $743.8M | SIBN | |
| Trailing P/E Ratio | N/M | 133.6x | DCTH | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +14.5% | +70.7% | DCTH | |
| Operating Margin (TTM) | -7.6% | 5.2% | DCTH | |
| Net Profit Margin | -6.2% | 6.0% | DCTH | |
| Return on Equity (ROE) | -7.7% | 5.4% | DCTH | |
| 52-Week Range Position | 82% ($11–$26) | 80% ($8–$23) | SIBN | |
| Beta / 30D Volatility | 0.74β · 77% Vol | 1.63β · 131% Vol | SIBN | |
| Unified Institutional Score | 38.3 / 100 (SELL) | 35.9 / 100 (SELL) | SIBN | |
| Trailing 12M Revenue (USD) | $221M | $110M | Scale | |
| Gross Profit Margin (TTM) | 79.4% | 87.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 5.0x EV/Rev | 1.60x PEG · 6.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$4.2M ($7.5M Net Debt (0.23x D/E)) | $20M ($53M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DCTH +21.43 pp
3M Horizon
SIBN +4.95 pp
6M Horizon
DCTH +19.67 pp
1Y Horizon
DCTH +93.63 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SIBN Revenue | DCTH Revenue | SIBN Op. Margin | DCTH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $60M | N/A | -21.6% | N/A | SIBN |
| FY2019 | $70M | N/A | -53.5% | N/A | SIBN |
| FY2020 | $70M | N/A | -52.6% | N/A | SIBN |
| FY2021 | $90M | $0M | -57.3% | -690.0% | SIBN |
| FY2022 | $110M | $0M | -56.0% | -1245.1% | SIBN |
| FY2023 | $140M | $0M | -33.8% | -1849.0% | SIBN |
| FY2024 | $170M | $40M | -21.1% | -33.4% | SIBN |
| FY2025 | $200M | $90M | -11.1% | 0.8% | DCTH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SIBN
BREAKOUT
Current IV
44.5%
IV Percentile
14th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact SIBN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DCTH
BREAKOUT
Current IV
109.3%
IV Percentile
43rd %ile
Put/Call OI Skew
0.11x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SIBN Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
Investor FAQ SIBN vs DCTH Key Questions & Quantitative Answers
As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over SI-BONE, Inc. (SIBN) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SIBN carries a Unified Composite Score of 38.3/100 (SELL) at $23.29 (N/M Forward P/E, -7.6% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While SIBN currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -7.6% operating margin) and revenue trajectory (+70.7% vs. +14.5% YoY). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both SIBN (38.3/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
DCTH leads the Growth & Scale pillar: SIBN posts +14.5% YoY revenue growth and +0.0% YoY earnings growth on $221M TTM revenue (79.4% gross margin, -7.6% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIBN cumulative revenue shifted +233.3% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, SIBN deploys N/A (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
DCTH screens cheaper on headline valuation multiples. SIBN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.0x EV/Revenue (-1.9% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIBN (-7.7% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, SIBN carries 44.5% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (0.74β · 77% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DCTH vs SIBN · Reverse Pair
SIBN vs KIDS
· Sector Peer
SIBN vs VREX
· Sector Peer
SIBN vs LIVN
· Sector Peer
DCTH vs CRMD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma